1999-2016年美国成人中高风险非酒精性脂肪性肝病患病率
基于NHANES 1999-2016及NHANES III数据,超声或美国脂肪肝指数判定NAFLD,FIB-4评估纤维化风险。NAFLD患病率从1999-2000年29.5%升至2015-2016年40.3%,中风险从6.26%升至14.17%,高风险从0.49%升至1.15%;高风险NAFLD与全因、心血管病特异及肝病特异死亡率升高相关。
要点
- NAFLD患病率从1999-2000年29.5%升至2015-2016年40.3%(APC 2.78%,P<.02)。
- 中风险NAFLD从6.26%升至14.17%,高风险从0.49%升至1.15%。
- 高风险NAFLD全因死亡HR 1.53、心血管病特异死亡HR 1.99、肝病特异死亡HR 4.57。
核心结论
- 中风险或高风险NAFLD患病率正在增加,并与全因、肝病相关及心血管病死亡率升高相关。
研究设计与样本
- 研究利用NHANES 1999-2016及NHANES III(1988-1994)数据,共纳入NHANES III的10,854人(平均年龄43.5岁;47.5%男性;75.7%非西班牙裔白人)。
- NAFLD由超声显示中至重度脂肪变性判定,无超声者由美国脂肪肝指数评分≥30判定。
- 肝纤维化采用FIB-4评分评估:FIB-4<1.3为低风险,1.3-2.67为中风险,>2.67为高风险。
- 年度百分比变化(APC)采用连接点回归模型计算。
主要发现
- NHANES III中37.7%有NAFLD,其中基于FIB-4,80%为低风险、18.6%为中风险、1.4%为高风险。
- 中或高风险NAFLD较低风险NAFLD更可能合并高血压、高脂血症、糖尿病、心血管疾病和代谢综合征(所有P<.02)。
- NAFLD患病率从1999-2000年29.5%升至2015-2016年40.3%(APC 2.78%,P<.02),中风险从6.26%升至14.17%(APC 5.34%,P<.02),高风险从0.49%升至1.15%(APC 9.72%,P<.02)。
- 进展性纤维化的独立预测因素为年龄(OR 1.11;95%CI 1.06-1.17;P=.001)和糖尿病(OR 2.28;95%CI 1.03-5.05;P=.04)。
- 与低风险NAFLD相比,高风险NAFLD与全因死亡(HR 1.53;95%CI 1.09-2.15;P=.01)、心血管病特异死亡(HR 1.99;95%CI 1.22-3.24;P<.01)及肝病特异死亡(HR 4.57;95%CI 1.03-28.79;P=.04)显著增加相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) subjects with fibrosis stage ≥2 are at high risk for mortality. We aimed to provide national estimates and temporal trends for NAFLD, based on different fibrosis severity. METHODS: Data from the National Health and Nutrition Examination Survey (NHANES) (1999-2016) and NHANES III (1988-1994) were utilized. NAFLD was determined by ultrasound showing moderate to severe steatosis. For those without ultrasound, NAFLD was determined by the U.S. Fatty Liver Index score of ≥30. Hepatic fibrosis was assessed using Fibrosis-4 (FIB-4) score (FIB-4 <1.3 = low risk; FIB-4 1.3-2.67 = moderate risk; and FIB-4 >2.67 = high risk). Annual percent change (APC) was calculated by using the joinpoint regression model. RESULTS: From NHANES III, 10,854 individuals were included (mean age 43.5 years; 47.5% male; 75.7% non-Hispanic White) and 37.7% had NAFLD. Among them, based on FIB-4, 80% had low-risk, 18.6% had moderate-risk, and 1.4% had high-risk NAFLD. NAFLD with moderate or high risk was more likely to have hypertension, hyperlipidemia, diabetes, cardiovascular disease, and metabolic syndrome than was low-risk NAFLD (all P < .02). NAFLD prevalence increased from 29.5% in 1999-2000 to 40.3% in 2015-2016 (APC, 2.78%; P < .02), moderate-risk NAFLD increased from 6.26% to 14.17% (APC, 5.34%; P < .02), and high-risk NAFLD increased from 0.49% to 1.15% (APC, 9.72%; P < .02). Independent predictors of advanced fibrosis were age (OR, 1.11; 95% CI, 1.06-1.17; P = .001) and diabetes (OR, 2.28; 95% CI, 1.03-5.05; P = .04). Compared with low-risk NAFLD, high-risk NAFLD was associated with significantly increased all-cause (HR, 1.53; 95% CI, 1.09-2.15; P = .01), cardiovascular disease-specific (HR, 1.99; 95% CI, 1.22-3.24, P < .01) and liver-specific (HR, 4.57; 95% CI, 1.03-28.79; P = .04) mortality. CONCLUSIONS: The prevalence of moderate- or high-risk NAFLD is increasing and is associated with increased all-cause, liver-related, and cardiovascular mortality.
引用
- Golabi P, Paik JM, Harring M, et al. Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016. Clin Gastroenterol Hepatol. 2021. PMID: 34929391. doi:10.1016/j.cgh.2021.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。